—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Regeneron Pharmaceuticals Inc (REGN) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for REGN, from the same nightly bakes the boards use. Research diary readings, not advice.

Versus its index HALO Growth 100 — the name, its sleeve and the index over day, week and month

Versus its index

The name against its Closelooknet index and its own sleeve — equal-weight, nightly closes.

HALO Growth 100 · as of 2026-10-06

DayWeekMonth3 months
REGN+1.7%−1.6%−10.8%+11.4%
Longevity & Healthspan−1.9%−3.5%−4.0%—
HALO Growth 100+0.5%+0.7%−4.9%—

Against the index: 2.3 pts behind on the week, 5.9 pts behind on the month; against its Longevity & Healthspan sleeve 6.8 pts behind on the month.

Returns from the index workers’ nightly closes; equal-weight sleeves. A relative reading from the research diary, not advice.

Mentioned on Closelooknet 1 piece · newest: Midday 10, “A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000” (2026-08-21)

Mentioned on Closelooknet

Where REGN appears in the diary — 1 piece, newest first. Every link is our own writing.

Dailies

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sector × region Health care in US: −2.1% week · −2.2% month · +3.3% quarter · +16.4% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
How it trades on rate days beta 0.67 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How REGN has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.67 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Regeneron Pharmaceuticals Inc moved 0.67% on average · correlation 0.19 · higher than 68% of US names
  • Beta, last 3 months 0.89 more rate-sensitive lately than over the year
  • On the 10 worst bond days −1.01% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −0.72% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against HALO Growth 100 · Longevity & Healthspan · 8 names with week and year-to-date

Peer group

HALO Growth 100 · Longevity & Healthspan

GLP-1 leaders, gene-editing platforms, diagnostics-at-scale, biopharma compounders. Demographics writes the demand curve.

Compared against REGN on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Regeneron Pharmaceuticals Inc

REGN in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Regeneron discovers, develops, manufactures and sells medicines across eye disease, immune and inflammatory conditions, cardiovascular and metabolic disorders, neurological and infectious disease, rare disease, cancer and blood disorders. Its marketed products include an eye injection for macular degeneration and related retinal conditions, an injection for atopic dermatitis and asthma, a skin-cancer treatment, a cholesterol-lowering injection and a rheumatoid arthritis treatment. It also runs research partnerships covering RNA-interference, gene-editing and radiopharmaceutical approaches with several smaller biotech firms. The company is based in Tarrytown, United States.
Where it sits in the stack
Regeneron carries no seat in our chip-focused index; it sits in the Longevity & Healthspan sleeve of the HALO Growth 100, our growth index outside the megacaps, alongside firms building treatments and diagnostics tied to ageing populations.
Who it is priced against
Closelooknet's peer group places it with GLP-1 leaders, gene-editing platforms, diagnostics-at-scale firms and other biopharma compounders, on the view that demographics sets the pace of demand; the names include Eli Lilly, Novo Nordisk, Vertex Pharmaceuticals, Amgen, Illumina, Zealand Pharma, Natera and Gerresheimer. The market also compares it with Pfizer.
Why Closelooknet tracks it
It holds seats in the HALO Growth 100 and the Nasdaq-100. It carries a Closelooknet score built across three modules so far, with quality reading strongest and valuation reading weakest. The diary quoted it once, in a Midday 10 edition, as one of several health-care names appearing on a large-cap new-high list.
What the diary watches
Whether the research collaborations on gene-editing and RNA-interference begin producing marketed products, and whether that shifts the valuation module away from being the weakest reading.

Regeneron Pharmaceuticals Inc (REGN) trades on US exchanges, classified under Healthcare. Constituent of HALO Growth 100.

The Closelooknet company score reads 60/100 composite (momentum 56, quality 72, valuation 51) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 3 analyst actions on the wire · latest: price target by Jefferies, 2026-10-01

The Street on this name

Analyst actions and the latest print for REGN from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Jefferies — target 930 from 870 Target raised to $930 from $870 (+25.5% to spot) 2026-10-01
  • Price target Argus — target 850 Target set to $850 (+12.1% to spot) 2026-10-01
  • Price target Bernstein SocGen Group — target 756 Target set to $756 (-5.4% to spot) 2026-08-14

3 actions on the analyst wire since 2026-08-13: 3 target changes. Analyst wire → · Earnings wire →

Dividends and capital return trailing yield 0.50%, quarterly · buybacks 3.97 bn USD in FY2025

Dividends and capital return

What REGN pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 3.70 USD per share · a 0.50% yield on the 2026-10-06 close 4 distributions, paid quarterly 2026-10-06
  • Change on the year +40.1% against the prior twelve months prior twelve months 2.64 USD per share
  • Last distribution 0.94 USD per share as the price series records it, within days of the ex-date 2026-08-18
  • By calendar year 2025: 3.52 USD (partial) · 2026: 2.82 USD to date first distribution recorded in the three-year window: 2025-02-20
  • Dividends paid, FY2025 370 m USD 8% of earnings
  • Buybacks, FY2025 3.97 bn USD 5.3% of today's market value
  • Share count −5.6% in FY2025 994 m USD of stock-based compensation in the year
  • Capital returned 4.34 bn USD · 106% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Regeneron Pharmaceuticals Inc (REGN)?

Regeneron Pharmaceuticals Inc trades as REGN on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is REGN in a Closelooknet index?

Yes — Regeneron Pharmaceuticals Inc is a constituent of HALO Growth 100, as of 2026-10-07.

What is Regeneron Pharmaceuticals Inc's Closelooknet composite score?

60 out of 100, with momentum 56, quality 72 and valuation 51 sub-scores, as of 2026-10-07. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does REGN trade against its moving averages?

In a correction — 15.5% off its high: 15.5% below its 52-week high and under its 50-day — a textbook 10-to-20% correction. As of 2026-10-05 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How is REGN doing against its Closelooknet index?

Over the past month Regeneron Pharmaceuticals Inc is −10.8% against −4.9% for the HALO Growth 100 — 5.9 points behind its index, as of 2026-10-06. Its Longevity & Healthspan sleeve is −4.0% over the same month. The “Versus its index” table on this page carries the day, the week and the month for the name, its sleeve and the index.

How does Regeneron Pharmaceuticals Inc compare with its peers?

Against its peer group (HALO Growth 100 · Longevity & Healthspan), Regeneron Pharmaceuticals Inc (REGN) sits 15.5% below its 52-week high, 7.6% below its 50-day average; Eli Lilly and Company (LLY) is 11.6% below, Amgen Inc (AMGN) is 9.9% below, Novo Nordisk A/S (NVO) is 39.3% below. Put any of them next to REGN in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Regeneron Pharmaceuticals Inc trade when bond yields rise?

Over the past year Regeneron Pharmaceuticals Inc had a beta of 0.67 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 68% of US names. On the 10 sessions in which long bonds fell most it moved −1.01% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

Where has Closelooknet written about Regeneron Pharmaceuticals Inc?

Regeneron Pharmaceuticals Inc appears in 1 Closelooknet piece, most recently Midday 10: A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000 (2026-08-21). What Closelooknet said most recently: Barchart's large-cap 52-week new-high list, as of 11:59 CDT, carries 31 names and reads like the ex-tech thesis printed as breadth: twelve are health care, biotech or pharma — ARGX, BDX, BIO, CORT, HALO, MRK, REGN, RVTY, THC, TVTX, TXG… (Midday 10, 2026-08-21). The "Mentioned on Closelooknet" block on this page lists the long reads, the reference entries and the dailies that name it.

What does Regeneron Pharmaceuticals Inc do?

Regeneron discovers, develops, manufactures and sells medicines across eye disease, immune and inflammatory conditions, cardiovascular and metabolic disorders, neurological and infectious disease, rare disease, cancer and blood disorders. Its marketed products include an eye injection for macular degeneration and related retinal conditions, an injection for atopic dermatitis and asthma, a skin-cancer treatment, a cholesterol-lowering injection and a rheumatoid arthritis treatment. It also runs research partnerships covering RNA-interference, gene-editing and radiopharmaceutical approaches with several smaller biotech firms. Closelooknet's peer group places it with GLP-1 leaders, gene-editing platforms, diagnostics-at-scale firms and other biopharma compounders, on the view that demographics sets the pace of demand; the names include Eli Lilly, Novo Nordisk, Vertex Pharmaceuticals, Amgen, Illumina, Zealand Pharma, Natera and Gerresheimer. The market also compares it with Pfizer.

Where does Regeneron Pharmaceuticals Inc sit in the AI build-out?

Regeneron carries no seat in our chip-focused index; it sits in the Longevity & Healthspan sleeve of the HALO Growth 100, our growth index outside the megacaps, alongside firms building treatments and diagnostics tied to ageing populations. It holds seats in the HALO Growth 100 and the Nasdaq-100. It carries a Closelooknet score built across three modules so far, with quality reading strongest and valuation reading weakest. The diary quoted it once, in a Midday 10 edition, as one of several health-care names appearing on a large-cap new-high list.

Does Regeneron Pharmaceuticals Inc pay a dividend?

Regeneron Pharmaceuticals Inc has paid 3.70 USD per share over the last twelve months, paid quarterly, a trailing yield of 0.50% on the 2026-10-06 close; the last distribution recorded in the price series was 0.94 USD on 2026-08-18. In fiscal 2025 the company paid 370 m USD in dividends and bought back 3.97 bn USD of its own shares, 106% of that year’s free cash flow. The share count fell 5.6% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Regeneron Pharmaceuticals Inc recently?

The most recent analyst action on Regeneron Pharmaceuticals Inc on the Closelooknet wire is a price target by Jefferies on 2026-10-01 (target 930 from 870). 3 actions on the analyst wire since 2026-08-13: 3 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for REGN, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

same Closelooknet index seat first, then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.